Analyst Ratings for BridgeBio Pharma (BBIO)
BBIO Rating Summary
BBIO Price Target Summary
- Highest: $157.00 (Barclays)
- Lowest: $57.00 (Scotiabank)
- Average: $99.78
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$99.78 (+50.6%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
Avg. $ Target:
$99.78 (+50.6%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | Canaccord | Whitney Ijem | New Coverage | Buy (N/A) |
104.00 (N/A) |
63.88 (66.27) |
3.74% | Details |
| 5/26/2026 | Raymond James | Martin Auster | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
70.28 (66.27) |
-5.71% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
